Capricor Therapeutics (NASDAQ:CAPR) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Capricor Therapeutics (NASDAQ:CAPR) announced its earnings results on Tuesday. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04), FiscalAI reports.

Capricor Therapeutics Stock Down 1.2%

NASDAQ CAPR traded down $0.38 on Tuesday, hitting $31.52. 1,054,237 shares of the stock were exchanged, compared to its average volume of 1,285,162. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The company has a 50-day moving average price of $31.57 and a 200-day moving average price of $23.69. The company has a market cap of $1.82 billion, a PE ratio of -13.95 and a beta of 0.48.

Wall Street Analyst Weigh In

CAPR has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, March 10th. B. Riley Financial increased their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the stock an “overweight” rating in a research note on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $46.09.

Insiders Place Their Bets

In other news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at approximately $260,669.10. The trade was a 75.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the transaction, the director owned 7,529 shares of the company’s stock, valued at approximately $240,928. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 172,529 shares of company stock worth $5,302,440 over the last 90 days. Company insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CAPR. Goldman Sachs Group Inc. raised its position in shares of Capricor Therapeutics by 39.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares in the last quarter. Legal & General Group Plc increased its stake in Capricor Therapeutics by 8.4% in the second quarter. Legal & General Group Plc now owns 41,273 shares of the biotechnology company’s stock valued at $410,000 after purchasing an additional 3,205 shares during the last quarter. Rhumbline Advisers increased its stake in Capricor Therapeutics by 7.3% in the second quarter. Rhumbline Advisers now owns 53,450 shares of the biotechnology company’s stock valued at $531,000 after purchasing an additional 3,636 shares during the last quarter. Marshall Wace LLP acquired a new stake in Capricor Therapeutics during the second quarter worth approximately $796,000. Finally, Jump Financial LLC raised its holdings in Capricor Therapeutics by 42.6% during the second quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock worth $2,309,000 after purchasing an additional 69,515 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.